NCT02120222View on ClinicalTrials.gov

Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 22, 2014

Primary Completion Date

April 8, 2018

Study Completion Date

April 8, 2018

Conditions
Recurrent Melanoma
Interventions
DRUG

selinexor

Given PO

OTHER

Correlative studies

Blood will be collected for pK and pDn analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.

Trial Locations (1)

43210

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus

Sponsors

Lead Sponsor

Kari Kendra
All Listed Sponsors
collaborator

Karyopharm Therapeutics Inc

INDUSTRY

lead

Kari Kendra

OTHER

NCT02120222 - Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter